Rabbit antithymocyte globulin-induced serum sickness disease and human kidney graft survival.

ABSTRACT:

Background

Rabbit-generated antithymocyte globulins (ATGs), which target human T cells, are widely used as immunosuppressive agents during treatment of kidney allograft recipients. However, ATGs can induce immune complex diseases, including serum sickness disease (SSD). Rabbit and human IgGs have various antigenic differences, including expression of the sialic acid Neu5Gc and α-1-3-Gal (Gal), which are not synthesized by human beings. Moreover, anti-Neu5Gc antibodies have been shown to preexist and be elicited by immunization in human subjects. This study aimed to assess the effect of SSD on long-term kidney allograft outcome and to compare the immunization status of grafted patients presenting with SSD following ATG induction treatment.

Methods

We analyzed data from a coho

SUBMITTER: Couvrat-Desvergnes G 

PROVIDER: S-EPMC4665787 | biostudies-literature | 2015 Dec

REPOSITORIES: biostudies-literature